What especially shook investors was the prospect that China may have closed the tech gap with the United States in AI and especially DeepSeek’s claim that it developed R1 for just $5.6 million—a far ...

President Trump’s chief cost-cutter cheered an effort to persuade federal workers to quit — in a fashion that closely ...

Robert F. Kennedy Jr., if confirmed as HHS secretary, could help food-as-medicine startups expand with wider government health plan coverage.

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

That agreement came amid a wave of smaller deals from GSK, Eli Lilly and lesser known ... Venture firms Andreessen Horowitz and General Catalyst, which secured 20% of all committed LP capital ...

MY TAKE: The partnership between Andreessen Horowitz and Eli Lilly exemplifies how corporations can bridge the Aha gap – in biotech. But to unlock potential in non-biotech industries ...

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

Eli Lilly pre-announced a sizable Q4 2024 revenue miss headed into the big J.P. Morgan healthcare investor conference, but the biopharma reported massive growth. A lot of the quarterly ...

Eli Lilly also signed a major deal ... giant Lilly announced that it is teaming up with venture capital firm Andreessen Horowitz to launch the Biotech Ecosystem Venture Fund to “focus on ...

Andreessen Horowitz ... it has also released a $500 million Biotech Ecosystem Venture Fund with Eli Lilly to place a focus on health technologies, but with the aspect of innovative applications.

Shares of Eli Lilly have been falling in recent months, but that could spell opportunity. Investors appear to be concerned that a new government could impact its growth potential. The business is ...

Eli Lilly announced preliminary fourth-quarter revenue of roughly $13.5 billion, or $400 million below the low end of its guidance, driven by slower-than-expected US market growth and lower ...